#China #Shanghai #lymphoma treatment #Jiahui International #CAR-T Immunotherapy

From Pakistan to Shanghai: A Journey of Hope

In a remarkable medical journey, Muhammad, a 36-year-old hospital worker from Quetta, Pakistan, has found a beacon of hope in the form of CAR-T immunotherapy at the Jiahui International Cancer Center in Shanghai. This treatment came after he had battled an aggressive recurrent form of lymphoma, known as diffuse large B-cell lymphoma (DLBCL), which had persisted through grueling standard treatments.

The Struggle with Lymphoma

Muhammad's ordeal began when his health deteriorated to Stage IVB, following several chemotherapy cycles and an unsuccessful bone marrow transplant. His condition escalated, spreading to his lungs, pleura, and bones, where he suffered from severe pain and limited options for effective treatment. Local medical professionals ultimately concluded that further conventional therapies would not be effective, suggesting he seek advanced treatment abroad. With approval from the Pakistan Medical Association, Muhammad embarked on an international medical journey.

Chosen Destination: Jiahui International Cancer Center

After examining potential treatment centers in various countries, Muhammad selected Jiahui. Several factors influenced this decision, including the facility's efficient consulting service and attentive patient care. This choice proved pivotal in his recovery journey.

Personalized Care and Treatment Plans

In light of Muhammad's complex health situation, Dr. Hao Siguo, the chief hematologist, tailored a specific CAR-T therapy plan for him after a teleconsultation. To optimize his condition for the procedure, a bridging therapy—combining chemotherapy and local radiation—was designed to reduce his tumor burden before the CAR-T cell infusion. This strategy notably lowered the risks associated with the infusion while enhancing the overall treatment efficacy.

Life-Changing CAR-T Infusion

Once his vital organ functions were deemed stable, a multidisciplinary team went ahead with his CAR-T therapy. On April 23, 2026, Muhammad underwent a personalized CAR-T cell infusion. Throughout his hospital stay, he experienced only mild, manageable symptoms linked with cytokine release syndrome, without severe neurotoxicity. Remarkable improvements in his health were observed swiftly; the severe cancer-related pain he endured subsided significantly, and his need for opioids dropped dramatically.

Follow-up tests conducted before his discharge revealed a significant reduction in tumor lesions and normalization of critical lab values, marking an incredible turnaround in his health.

A Supportive Environment

During his treatment, Jiahui's international care team was dedicated to addressing every aspect of his needs, providing professional translation services and catering to his cultural and religious requirements. Muhammad expressed his gratitude for the supportive environment provided in China, noting, "The Chinese are very helpful. The doctors, nurses, and staff were extraordinarily supportive."

Looking Ahead

He was discharged on May 7, 2026, and will continue regular imaging and follow-up care back in Pakistan. Muhammad’s extraordinary journey highlights the capabilities of Jiahui International Cancer Center in administering CAR-T therapy for refractory lymphoma and underscores their commitment to standardized, patient-centered, cross-border medical assistance.

To learn more about their services and patient care, visit Jiahui Health or contact their International Office for assistance via email or WhatsApp.

Muhammad's story is not just a testament to medical innovation but also a beacon of hope for many battling similar health challenges. His experience exemplifies how personalized treatment can lead to miraculous recoveries, tracing the path for more patients to follow.